Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + interferon + octreotide
- Development stage
- Unknown
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular, Intravenous
01
Overview
A combination therapy consisting of thalidomide, interferon (specifically alpha-interferon), and octreotide. This regimen has been investigated primarily for the treatment of unresectable hepatocellular carcinoma. Thalidomide contributes anti-angiogenic properties by suppressing vascular endothelial growth factor (VEGF) and modulating immune responses. Interferon provides immunomodulatory effects, while octreotide (a somatostatin analogue) may reduce gastrointestinal blood flow and potentially has anti-angiogenic properties. Despite having a favorable toxicity profile, clinical trials have shown this combination has limited efficacy in hepatocellular carcinoma.
- Other names
- thalidomide + alpha interferon + octreotidethalidomide + interferon alfa + octreotide combinationthalidomide + alpha interferon +/- octreotide
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)CRBN (Cereblon)SSTR5 (Somatostatin receptor 5)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on thalidomide + interferon + octreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + interferon + octreotide.